Results 151 to 160 of about 3,931,498 (308)

Power to the people : evidence from a randomized field experiment of a community-based monitoring project in Uganda [PDF]

This paper analyzes the importance of strengthening the relationship of accountability between health service providers and citizens for improving access to and quality of health care.
Bjorkman, Martina, Svensson, Jakob
core  

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

Wearable Sensors for Health Monitoring. [PDF]

Biosensors (Basel)
Abreu C, Bédard C, Lourme JC, Piro B.
europepmc   +1 more source

Abstracts : Policy Research working paper series - numbers 2883 - 2933 [PDF]

This paper contains abstracts of Policy Research Working Paper series, numbers 2883 - 2933.Environmental Economics&Policies,Health Economics&Finance,Poverty Assessment,Governance Indicators,Health Monitoring ...
anonymous
core  

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Wearable Devices and New Frontiers in Smart Health Monitoring. [PDF]

Sensors (Basel)
Holgado-Terriza JA, Pico-Valencia P, Liang Z.   +2 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Latent Monotonic Feature Discovery for Structural Health Monitoring. [PDF]

Sensors (Basel)
Toussaint G, Knobbe A.
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Flexible Sensors for Battery Health Monitoring. [PDF]

Nanomicro Lett
Wang X, Zhang H, Qi X, Chen S, Huang Z, Zhao J, Wang Y, Wu D, Zheng G, Xue C, Zhou J, Wang H, Yin Z, Gao L.   +13 more
europepmc   +1 more source